Risuteganib (Luminate®)
Intermediate Dry Age-Related Macular Degeneration (AMD)
Phase 2b/3Active
Key Facts
Indication
Intermediate Dry Age-Related Macular Degeneration (AMD)
Phase
Phase 2b/3
Status
Active
Company
About Allegro Ophthalmics
Allegro Ophthalmics is a private, clinical-stage biotech developing a novel class of 'mitochondrial stabilizer' therapies for major ocular diseases. Its lead asset, risuteganib, has shown promise in Phase 2a for intermediate dry AMD and is now in Phase 2b/3 planning under an FDA Special Protocol Assessment (SPA), with a licensee advancing Phase 3 trials in China. The company's platform targets integrin dysregulation to address mitochondrial dysfunction and oxidative stress, aiming to provide treatment options for patients who inadequately respond to current therapies.
View full company profile